![]() |
|
|
Vol. 286, Issue 2, 585-592, August 1998
Pain Research, As a follow-up study to an earlier report that racemic fenfluramine can
acutely potentiate the analgesic effects of morphine in humans, we
investigated the effects of fenfluramine on the development of
tolerance to morphine analgesia in rats. Antinociceptive effect, as
measured by the tail-flick latency, was studied over 8 days in rats
that received continuous i.v. infusion of 1) 22 mg/kg/day of morphine,
2) 20 mg/kg/day of fenfluramine, 3) both drugs concomitantly or 4)
saline. Infusion with morphine alone resulted in a peak analgesia of
100% maximal possible effect, which declined with time; full tolerance
was reached by day 4. Fenfluramine treatment alone had no effect.
Fenfluramine coinfusion attenuated the development of tolerance to
morphine; >70% maximal possible effect was still present on day 4. The effect of fenfluramine coinfusion occurred in the absence of a
significant increase in plasma or brain morphine concentration, or a
decrease in the accumulation of morphine's putative antagonistic
metabolite, morphine-3-glucuronide. In another set of infusion
experiments, rats were challenged with a single i.p. dose of morphine
to characterize the morphine dose-response curves at 10 hr following
4-day i.v. infusion of 1) 22 mg/kg/day of morphine, 2) 20 mg/kg/day
fenfluramine, 3) morphine plus fenfluramine or 4) saline. An acute i.p.
morphine challenge dose response experiment was also conducted in
naïve control rats and in rats receiving a concomitant i.p.
injection of fenfluramine (2.4 mg/kg). Coinjection of fenfluramine
acutely potentiated the antinociceptive potency of morphine. However,
potentiation alone does not fully account for the apparent attenuation
of tolerance during morphine i.v. infusion. ED50 of
morphine was elevated to 7.0 mg/kg in the morphine-infused rats
compared to 2.4 mg/kg in saline-infused rats. Coinfusion of
fenfluramine increased ED50 to only 3.7 mg/kg. These
results demonstrate that fenfluramine significantly attenuates
tolerance development to morphine by modulating the pharmacological
process responsible for tolerance development to morphine.
0022-3565/98/2862-0585$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
J.-Y. Li, C.-H. Wong, E. Y.-K. Huang, Y.-C. Lin, Y.-L. Chen, P. P. C. Tan, and J.-C. Chen Modulations of Spinal Serotonin Activity Affect the Development of Morphine Tolerance Anesth. Analg., June 1, 2001; 92(6): 1563 - 1568. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-X. Wang, S. S. Bowersox, M. Pettus, and D. Gao Antinociceptive Properties of Fenfluramine, a Serotonin Reuptake Inhibitor, in a Rat Model of Neuropathy J. Pharmacol. Exp. Ther., December 1, 1999; 291(3): 1008 - 1016. [Abstract] [Full Text] |
||||